Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where M. González is active.

Publication


Featured researches published by M. González.


Leukemia | 2012

The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation

Thomas Lion; F Watzinger; S Preuner; Hermann Kreyenberg; M. G. J. Tilanus; R de Weger; J van Loon; L de Vries; H Cavé; C Acquaviva; Mark Lawler; M Crampe; Anna Serra; B Saglio; F Colnaghi; Andrea Biondi; J J M van Dongen; M.E.L. van der Burg; M. González; Miguel Alcoceba; Gisela Barbany; Monica Hermanson; Eddy Roosnek; Colin G. Steward; J Harvey; F Frommlet; Peter Bader

Hematopoietic stem cell transplantation is becoming an increasingly important approach to treatment of different malignant and non-malignant disorders. There is thus growing demand for diagnostic assays permitting the surveillance of donor/recipient chimerism posttransplant. Current techniques are heterogeneous, rendering uniform evaluation and comparison of diagnostic results between centers difficult. Leading laboratories from 10 European countries have therefore performed a collaborative study supported by a European grant, the EuroChimerism Concerted Action, with the aim to develop a standardized diagnostic methodology for the detection and monitoring of chimerism in patients undergoing allogeneic stem cell transplantation. Following extensive analysis of a large set of microsatellite/short tandem repeat (STR) loci, the EuroChimerism (EUC) panel comprising 13 STR markers was established with the aim to optimally meet the specific requirements of quantitative chimerism analysis. Based on highly stringent selection criteria, the EUC panel provides multiple informative markers in any transplant setting. The standardized STR-PCR tests permit detection of donor- or recipient-derived cells at a sensitivity ranging between 0.8 and 1.6%. Moreover, the EUC assay facilitates accurate and reproducible quantification of donor and recipient hematopoietic cells. Wide use of the European-harmonized protocol for chimerism analysis presented will provide a basis for optimal diagnostic support and timely treatment decisions.


British Journal of Haematology | 2008

Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma

Adriana Armellini; M. E. Sarasquete; Ramón García-Sanz; M C Chillón; A. Balanzategui; Miguel Alcoceba; Marta Fuertes; Rosa López; Jm Hernandez; Javier Fernández-Calvo; Magdalena Sierra; Marta Megido; Alberto Orfao; Norma C. Gutiérrez; M. González; J. F. San Miguel

RAN, ZHX2 and RCBTB2 (CHC1L) expression was evaluated by quantitative real time reverse transcription polymerase chain reaction in plasma cells from 85 monoclonal gammopathies: 58 symptomatic multiple myeloma (MM) (52 untreated, six relapsed), eight smouldering MM, five monoclonal gammopathy of undetermined significance, four plasma cell leukaemias and 10 myeloid cell lines. ZHX2 was weakly expressed in high‐risk/proliferative disease compared to low‐risk or indolent disease. High ZHX2 expression was associated with better response and longer survival after high‐dose therapy. RCBTB2 expression was weaker in hyperdiploid versus non‐hyperdiploid cases while RAN was more expressed in symptomatic MM and cell lines.


Clinical and Experimental Dermatology | 2009

Primary cutaneous T‐cell lymphoproliferative disorder of donor origin after allogeneic haematopoietic stem‐cell transplantation

A. Santos‐Briz; A. Romo; P. Antúnez; C. Román; Miguel Alcoceba; J. L. Garcia; L. Vazquez; M. González; P. Unamuno

A 56‐year‐old male patient had a history of mantle‐cell lymphoma, which was treated with polychemotherapy and reduced‐intensity conditioning allogeneic haematopoietic stem cell transplantation (ASCT) from his healthy sister with an identical human leucocyte antigen profile. Six years after transplantation, the patient developed asymptomatic eczema‐like cutaneous lesions. Histologically the lesions contained a dense superficial lichenoid infiltrate, mainly consisting of CD4+ atypical medium to large lymphocytes showing indented hyperchromatic nuclei. In situ hybridization for Epstein–Barr virus was negative. PCR amplification of the T‐cell receptor‐γ chain gene from several lesions revealed a monoclonal rearrangement without clonal variation. Two‐colour fluorescence in situ hybridization (X and Y chromosomes) and microsatellite genotyping were used to compare samples from the patient (transplant recipient), his sister (donor) and the skin biopsy sample, which confirmed that the origin of the neoplastic cells was the donor graft. To our knowledge, this is the first case of post‐transplant primary cutaneous T‐cell lymphoproliferative disorder after ASCT.


British Journal of Haematology | 2017

Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group

Sara Alonso-Álvarez; Laura Magnano; Miguel Alcoceba; Marcio Andrade-Campos; Natalia Espinosa-Lara; Guillermo Rodríguez; Santiago Mercadal; Itziar Carro; Juan M. Sancho; Miriam Moreno; Antonio Salar; Francesc Garcia-Pallarols; Reyes Arranz; Jimena Cannata; María José Terol; Ana Isabel Teruel; Antonia Rodriguez; Ana Jiménez-Ubieto; Sonia González de Villambrosia; Jose Luis Bello; Lourdes López; Silvia Monsalvo; Silvana Novelli; Erik de Cabo; Maria Stefania Infante; Emilia Pardal; María García-Álvarez; Julio Delgado; M. González; Alejandro Martín

The diagnostic criteria for follicular lymphoma (FL) transformation vary among the largest series, which commonly exclude histologically‐documented transformation (HT) mandatorily. The aims of this retrospective observational multicentre study by the Spanish Grupo Español de Linfoma y Transplante Autólogo de Médula Ósea, which recruited 1734 patients (800 males/934 females; median age 59 years), diagnosed with FL grades 1–3A, were, (i) the cumulative incidence of HT (CI‐HT); (ii) risk factors associated with HT; and (iii) the role of treatment and response on survival following transformation (SFT). With a median follow‐up of 6·2 years, 106 patients developed HT. Ten‐year CI‐HT was 8%. Considering these 106 patients who developed HT, median time to transformation was 2·5 years. High‐risk FL International Prognostic Index [Hazard ratio (HR) 2·6, 95% confidence interval (CI): 1·5–4·5] and non‐response to first‐line therapy (HR 2·9, 95% CI: 1·3–6·8) were associated with HT. Seventy out of the 106 patients died (5‐year SFT, 26%). Response to HT first‐line therapy (HR 5·3, 95% CI: 2·4–12·0), autologous stem cell transplantation (HR 3·9, 95% CI: 1·5–10·1), and revised International Prognostic Index (HR 2·2, 95% CI: 1·1–4·2) were significantly associated with SFT. Response to treatment and HT were the variables most significantly associated with survival in the rituximab era. Better therapies are needed to improve response. Inclusion of HT in clinical trials with new agents is mandatory.


Tissue Antigens | 2011

Frequency of HLA-A, -B and -DRB1 specificities and haplotypic associations in the population of Castilla y León (northwest-central Spain).

Miguel Alcoceba; Luis Marín; A. Balanzategui; M. E. Sarasquete; M C Chillón; Patricia Martín-Jiménez; Noemi Puig; Carlos Santamaría; Rocío Corral; Ramón García-Sanz; J. F. San Miguel; M. González

The frequencies of human leukocyte antigen (HLA) class I and class II specificities and haplotypic associations were determined in 1940 unrelated donors from Castilla y León and compared with other Iberian, Mediterranean and European populations. Specificities were determined using polymerase chain reaction reverse sequence-specific oligonucleotide or polymerase chain reaction sequence-specific primer techniques. In the analysis, 19, 29 and 13 specificities were found for HLA-A, -B and -DRB1, respectively, with HLA-A*02 (26%), -A*01 (11%), -B*44 (16%), -B*35 (10%), -DRB1*07 (16%) and -DRB1*13 (14%) showing the highest frequencies. In addition, 10 common HLA-A-B-DRB1 haplotypic associations were observed, A*01-B*08-DRB1*03 (3%) and A*29-B*44-DRB1*07 (3%) being the most frequent ones. These findings indicate that the population of Castilla y León is genetically equidistant from the Portuguese and other Spanish populations and shares a common origin with other Iberian populations, in which European, Mediterranean and North African genetic components are present; this is in agreement with the historical and genetic background of the population. These data contribute to a better understanding of the genetic structure of the Iberian Peninsula and provide a healthy control population from our region that should be useful for the study of disease associations.


Tissue Antigens | 2008

The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease

Miguel Alcoceba; Luis Marín; A. Balanzategui; M. E. Sarasquete; Patricia Martín-Jiménez; M C Chillón; Rocío Corral; E. Pérez-Persona; F.J. Fernandez-Calvo; Jm Hernandez; Joan Bladé; Juan-José Lahuerta; M. González; J. F. San Miguel; Ramón García-Sanz

The human leukocyte antigen (HLA) system could play an essential role in multiple myeloma (MM) disease control. This report describes the results comparing HLA-DRB1 phenotypic frequencies in 181 MM patients (53 smoldering/indolent MM and 128 symptomatic MM patients) and healthy individuals. Higher DRB1*01 phenotypic frequencies were found in the smoldering patients compared with symptomatic MM patients (38% vs 14%, P = 0.001) and with the healthy individuals (38% vs 22%, P = 0.01). Additionally, higher DRB1*07 phenotypic frequencies were found in symptomatic MM compared with control population (38% vs 28%, P = 0.01). The present data suggest that HLA-DRB1*01 individuals may have a better ability to efficiently present myeloma-related antigens to immunocompetent cells, which could favor a better immune response against the tumor. This would translate into a more appropriate disease control associated with more indolent disease and prolonged survival.


Haematologica | 1998

Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection

J. Ciudad; Alberto Orfao; Belén Vidriales; Macedo A; A. Martínez; M. González; Mc Lopez-Berges; B. Valverde; J. F. San Miguel


Haematologica | 2006

The association of increased p14ARF/p16INK4a and p15INK4a gene expression with proliferative activity and the clinical course of multiple myeloma

M. E. Sarasquete; Ramón García-Sanz; Adriana Armellini; Marta Fuertes; Patricia Martín-Jiménez; Magdalena Sierra; M Del Carmen Chillon; Miguel Alcoceba; A. Balanzategui; Fernando Ortega; Jm Hernandez; Anna Sureda; Luis Palomera; M. González; J. F. San Miguel


Haematologica | 1999

Cryptic insertion (15;17) in a case of acute promyelocytic leukemia detected by fluorescence in situ hybridization.

Norma C. Gutiérrez; J.L. García; Carmen Chillón; Sandra Muntión; M. González; Jm Hernandez


Acta Horticulturae | 2007

POSTHARVEST BEHAVIOR OF THREE PAPAYA CULTIVARS PRODUCED IN MESH GREENHOUSE IN TENERIFE (CANARY ISLANDS, SPAIN)

J. Rancel Delgado; Ma.G. Lobo Rodrigo; Ma.C. Rodríguez Pastor; M. González

Collaboration


Dive into the M. González's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A. Balanzategui

Spanish National Research Council

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge